Cargando…
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
BACKGROUND: Treatment of hepatocellular carcinoma (HCC) varies widely depending on the patient's condition. In recent years, combination therapy with immune checkpoint inhibitors has emerged as the treatment of choice due to its superior antitumor effects for unresectable HCC (uHCC). Conversion...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236104/ https://www.ncbi.nlm.nih.gov/pubmed/37266831 http://dx.doi.org/10.1186/s40792-023-01678-9 |